3
views
0
recommends
+1 Recommend
0 collections
    0
    shares
      • Record: found
      • Abstract: found
      • Article: not found

      State transition model: vorapaxar added to standard antiplatelet therapy to prevent thrombosis post myocardial infarction or peripheral artery disease.

      Read this article at

      ScienceOpenPublisherPubMed
      Bookmark
          There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.

          Abstract

          To evaluate long-term health benefits and risks of adding vorapaxar (VOR) to the standard care antiplatelet therapy (SC) of aspirin and/or clopidogrel, among a population with a recent myocardial infarction (MI) and/or peripheral artery disease (PAD).

          Related collections

          Author and article information

          Journal
          Curr Med Res Opin
          Current medical research and opinion
          Informa UK Limited
          1473-4877
          0300-7995
          September 2017
          : 33
          : 9
          Affiliations
          [1 ] a Evidera , Bethesda , MD , US.
          [2 ] b Merck & Co. Inc. , North Wales , PA , US.
          [3 ] c Evidera , London , UK.
          Article
          10.1080/03007995.2017.1301902
          28277861

          Comments

          Comment on this article